Application No.: 10/584,415 Amendment Under 37 C.F.R. §1.111 Art Unit: 1614

Attorney Docket No.: 062522

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions of claims in the application.

1-4. (Cancelled)

5. (Currently Amended) A method of treating a disorder associated with the activation of γ-

secretase by inhibiting the formation of an active complex of y-secretase using comprising the

step of:

administering an effective amount of a cholesterol synthesis inhibitor or a protein

geranylgeranylation regulator to a patient in need of inhibiting the γ -secretase activity in a nerve

cell.

6. (Currently Amended) The method treating a disorder associated with the activation of γ -

secretase by according to claim 5, wherein the method is for inhibiting the said inhibiting of said

formation of an active complex of γ-secretase occurs in lipid rafts.

7. (Currently Amended) The method of inhibiting the formation of an active complex of y-

secretase treating a disorder associated with the activation of γ-secretase according to claim 5,

wherein the cholesterol synthesis inhibitor or the protein geranylgeranylation regulator is one or

more kinds of medical agents selected from a group consisting of an HMG-CoA synthetase

inhibitor, an HMG-CoA reductase inhibitor, a squalene synthetase inhibitor, a squalene

- 3 -

Application No.: 10/584,415 Amendment Under 37 C.F.R. §1.111

Art Unit: 1614 Attorney Docket No.: 062522

epoxydase inhibitor, a lanosterol synthetase inhibitor, an AMPK activator, a farnesyl

pyrophosphate synthetase inhibitor and a geranylgeranyl transferase inhibitor.

8. (Currently Amended) The method of inhibiting the formation of an active complex of γ -

secretase treating a disorder associated with the activation of γ -secretase according to claim 5,

wherein the cholesterol synthesis inhibitor or the protein geranylgeranylation regulator is an

HMG-CoA reductase inhibitor.

9. (Currently Amended) The method of inhibiting the formation of an active complex of y-

secretase treating a disorder associated with the activation of γ -secretase according to claim 5,

wherein the cholesterol synthesis inhibitor or the protein geranylgeranylation regulator is

pitavastatin.

10-14. (Cancelled)

15. (Withdrawn) A method of screening a substance having an effect of inhibiting the formation

of an active complex of γ-secretase comprising assaying an activity of inhibiting cholesterol

synthesis.

16. (Withdrawn) The method of screening according to claim 15, wherein an activity of

- 4 -

Application No.: 10/584,415 Amendment Under 37 C.F.R. §1.111

Art Unit: 1614 Attorney Docket No.: 062522

inhibiting cholesterol synthesis is an activity of inhibiting synthesis of cholesterol to be

accumulated in lipid rafts.

17. (Withdrawn) The method of screening according to claim 15, wherein an activity of

inhibiting cholesterol synthesis is an inhibiting activity selected from a group consisting of an

activity of inhibiting HMG-CoA synthetase, an activity of inhibiting HMG-CoA reductase, an

activity of inhibiting squalene synthetase, an activity of inhibiting squalene epoxydase, an

activity of inhibiting lanosterol synthetase, an activity of inhibiting AMPK activator and an

activity of inhibiting farnesyl pyrophosphate synthetase.

18. (Withdrawn) The method of screening according to claim 15, wherein an activity of

inhibiting cholesterol synthesis is an activity of inhibiting HMG-CoA reductase.

19. (Withdrawn) A method of screening a cholesterol synthesis inhibitor, a protein

geranylgeranylation regulator or an HMG-CoA reductase inhibitor, comprising screening an

effect of inhibiting the formation of an active complex of γ -secretase.

20. (Withdrawn) A method of screening a cholesterol synthesis inhibitor selected from a group

consisting of an HMG-CoA synthetase inhibitor, an HMG-CoA reductase inhibitor, a squalene

synthetase inhibitor, a squalene epoxydase inhibitor, a lanosterol synthetase inhibitor, an AMPK

activator, a farnesyl pyrophosphate synthetase inhibitor and a geranylgeranyl transferase

- 5 -

Application No.: 10/584,415

Art Unit: 1614

Amendment Under 37 C.F.R. §1.111

Attorney Docket No.: 062522

inhibitor, comprising assaying an effect of inhibiting the formation of an active complex of y-

secretase.

21. (Withdrawn) A method of screening an HMG-CoA reductase inhibitor comprising assaying

an effect of inhibiting the formation of an active complex of γ -secretase.

22. (Withdrawn) A method of screening an effect of a test substance on γ-secretase comprising

measuring the distribution of constituents required by γ -secretase in the cell for the formation of

an active complex thereof by adding the test substance to cultured cells.

23. (Withdrawn) The method according to claim 22, wherein the constituents required for the

formation of an active complex of γ-secretase are one or more kinds of substances selected from

a group consisting of nicastrin, APH-1 and Pen-2.

- 6 -